Iambic Therapeutics filed for a Nasdaq IPO, aiming to bring its AI-powered, robotics-enabled oncology drug discovery platform to public markets. The San Diego-based company plans to list under the ticker IAM and disclosed that it has raised $461.8 million since its 2019 founding. Central to the filing is IAM1363, an oral, brain-penetrating small molecule in Phase I/Ib across solid tumors targeting HER2-altered cancers. The company also described earlier programs targeting KIF18A and CDK2/4, with timelines pointing toward potential additional clinical starts. Iambic’s value narrative relies heavily on partnerships, including AbbVie’s collaboration and prior deals with Takeda and Lundbeck, positioning the platform as commercially validated rather than purely speculative. The IPO filing adds another datapoint to the 2026 biotech IPO cycle, where AI-first discovery and clinical-stage pipelines are increasingly being packaged for investor scrutiny.